PA
ADMA icon

Parallel Advisors’s ADMA Biologics ADMA Stock Holding History

Parallel Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.51K Buy
501
+51
+11% +$805 ﹤0.01% 3072
2025
Q4 		$8.21K Buy
450
+29
+7% +$489 ﹤0.01% 2686
2025
Q3 		$6.17K Sell
421
-131
-24% -$2.25K ﹤0.01% 2705
2025
Q2 		$10.1K Buy
552
+32
+6% +$653 ﹤0.01% 2475
2025
Q1 		$10.3K Buy
520
+66
+15% +$1.14K ﹤0.01% 2424
2024
Q4 		$7.79K Buy
454
+21
+5% +$395 ﹤0.01% 2492
2024
Q3 		$8.66K Buy
433
+65
+18% +$1.01K ﹤0.01% 2444
2024
Q2 		$4.11K Buy
368
+128
+53% +$1.07K ﹤0.01% 2592
2024
Q1 		$1.58K Hold
240
– – ﹤0.01% 2858
2023
Q4 		$1.08K Sell
240
-721
-75% -$2.67K ﹤0.01% 2917
2023
Q3 		$3.44K Hold
961
– – ﹤0.01% 2634
2023
Q2 		$3.55K Hold
961
– – ﹤0.01% 2555
2023
Q1 		$3.18K Buy
961
+120
+14% +$415 ﹤0.01% 2585
2022
Q4 		$3.26K Hold
841
– – ﹤0.01% 2495
2022
Q3 		$2K Buy
+841
New +$2.02K ﹤0.01% 2569
2022
Q2 		– Sell
-11,954
Closed -$22K – 2947
2022
Q1 		$22K Buy
+11,954
New +$18.6K ﹤0.01% 1674

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Parallel Advisors's ADMA Position: Q1 2026 in Review

Parallel Advisors increased its ADMA Biologics (ADMA) stake by 11% in Q1 2026, buying an estimated $805 and bringing the position to 501 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3072.

Parallel Advisors first reported a position in ADMA in Q1 2022 and has held it in 16 quarters since. The position peaked at $22K in Q1 2022. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Parallel Advisors held 501 shares of ADMA Biologics worth $4.51K as of Q1 2026.
  • Parallel Advisors bought 51 ADMA Biologics shares in Q1 2026, an estimated $805.
  • ADMA Biologics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3072 holding.
  • Parallel Advisors first reported a position in ADMA Biologics in Q1 2022 and has held it in 16 quarters since.
  • Parallel Advisors's ADMA Biologics position peaked at $22K in Q1 2022.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.